Drugs / Filgotinib
Drug research

Filgotinib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as GLPG0634; GS-6034; Jyseleca®

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseNCT02914561LKFTPhase 3Completed2022-11-11Actual
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in RemissionNCT05479058LKFTPhase 3Terminated2023-10-09Actual
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisNCT03926195LKFTPhase 2Completed2020-08-14Actual
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsNCT02065700LKFTPhase 2Completed2023-01-19Actual
Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseNCT02914600LKFTPhase 3Terminated2023-08-01Actual
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel DiseaseNCT03201445LKFTPhase 2Terminated2020-11-20Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.